The CYP19 gene, located on chromosome 15, encodes the The aromatase enzyme catalyses the conversion of enzyme P450 aromatase, which catalyses the biosynthesis of androgens to oestrogens in the oestrogen biosynthesis pathoestrogens from androgens in three sequential steps (described way. Because increased exposure to oestrogens is considered in ref. 9). Aromatase P450 is present in the endoplasmic to be a risk factor for breast cancer, the human aromatase reticulum of cells in which it is expressed, including the gene (CYP19) is a plausible candidate for low penetrance granulosa cells and corpus luteum of the ovary, the Leydig breast cancer susceptibility. Preliminary reports have cells of the testis, the placenta, various sites in the brain and suggested that specific alleles of a TTTA repeat may be in adipose tissue. Different forms of oestrogens are synthesized associated with differences in breast cancer risk. We have from different androgen substrates in the various tissues. For identified two new polymorphisms in the CYP19 gene: a instance, oestrone is synthesized from androstenedione in TCT insertion/deletion in intron 4 and a G→T substitution adipose tissue, oestradiol from testosterone in granulosa cells in intron 6, which have rare allele frequencies of 0.35 and and oestriol from 16α-hydoxylated androgens in the placenta.
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0.45, respectively, in the British population. Comparison
The CYP19 gene has 10 exons and transcription begins in was made between the frequencies of these alleles and exon 2. Tissue specificity is achieved using alternative splicing those of the TTTA repeat in up to 599 breast cancer of exon 1 combined with different tissue-specific promoters cases and 433 normal controls from the East Anglian, (reviewed in ref. 10) . Several mutations in the CYP19 gene British population. We found strong linkage dishave been identified which result in an autosomal recessive equilibrium between the alleles of these three loci, but no form of female pseudohermaphroditism and virilization of the significant association of any alleles with breast cancer mother during pregnancy due to impaired or absent aromatase risk. The maximum odds ratios observed were: 1.03 (95% activity. In addition, at puberty the affected female may show CI 0.68-1.55) for the intron 4 TCT insertion/deletion signs of virilization and have pubertal failure, hypergonadopolymorphism [del/del versus ins/ins]; 1.56 (95% CI trophic hypogonadism, polycystic ovaries and tall stature. 0.63-3.83) for the intron 4 [TTTA] 10 allele; 1.29 (95% CI (11) (12) (13) (14) .
0.75-2.21) for the intron 6 G→T polymorphism [TT versus
Two polymorphic sites have been used in breast cancer GG]. We conclude that the CYP19 gene has no major studies: (i) a tetranucleotide repeat polymorphism, [TTTA] n , role in common breast cancer incidence in the British population.
located in intron 4 of the CYP19 gene (15); and (ii) a C826T variation in exon 7 which gives rise to the amino acid substitution Arg264Cys and is observed by sequencing and Introduction SSCP analysis (9, (16) (17) (18) . There have been numerous reports of different TTTA repeat alleles being associated with variation Breast cancer is a common disease that will affect 8% of in breast cancer risk: Kristensen et al. (19) found that carrying British women. However, less than 5% of breast cancer the [TTTA] 12 allele was associated with an increased risk of incidence can be explained by rare, highly penetrant genes breast cancer in their Scandinavian population [odds ratio such as BRCA2 and TP53 (1, 2) . In principle, common, low (OR) 2.42, 95% confidence interval (95% CI) 1.03-5.80 ]. This penetrance genes could explain the majority of breast cancer was confirmed in a study by cases.
where the [TTTA] 12 allele was over-represented in breast It is widely accepted that oestrogens are involved in the cancer cases (OR 1.84, 95% CI 1.02-3.32), but refuted by development of breast tumours and increased lifetime exposure , who found that [TTTA] 12 to endogenous oestrogens is known to increase risk of breast occurred at a greater frequency in their control population. cancer (3, 4) . Epidemiological studies have identified several Haiman et al. (20) also found an increase in breast cancer risk factors affecting lifetime exposure that increase the risk of associated with the [TTTA] 10 allele (OR 4.03, 95% CI 1.52-breast cancer. These include: early age at menarche; late 10.67) and Siegelmann-Danieli and Buetow (21) reported a age at first pregnancy; late age at menopause; nulliparity; greater frequency of the [TTTA] assessed by testing for a trend in breast cancer risk with repeat length by Sourdaine et al. (17) found one Arg264Cys heterozygote in fitting a parameter for repeat length (averaged over the two chromosomes) in five breast tumours, but no polymorphism was seen in an logistic regression. Linkage disequilibrium between pairs of allelic sites was equal number of controls, suggesting a low Cys264 allele estimated using the correlation coefficient ∆ (23). Meta-analysis was performed frequency in the British population. In contrast, Watanabe by log linear regression. Odds ratios were estimated for specific alleles versus all others and each study was treated as a separate stratum.
et al. (18) found the Cys264 allele frequency to be 30% in a Japanese population sample. Seigelmann-Danieli and Buetow (21) also reported the variant in US breast cancer cases. Results Although creating a non-conservative amino acid substitution, Polymorphism discovery this polymorphism has no apparent effect on aromatase activity Initially all samples were genotyped for the [TTTA] n tract in or response to aromatase inhibitors (17, 18) , nor is it associated intron 4 with the PolyF and PolyR primers. TTTA repeats with breast cancer risk in Japanese women (18) . In this present ranging from 7-13 were observed and the frequencies are study we set out to investigate possible associations between given in Table I . In order to correlate the microsatellite band common CYP19 polymorphisms and breast cancer risk in the sizes with TTTA repeat length, homozygotes for the two most British population.
common alleles (Figure 1a ), allele 1 (the smallest) and allele 6, were sequenced. polymorphism was found in these samples (i.e. we observed
The second series is a group of 384 patients retrospectively ascertained through the East Anglian Cancer Registry, as part of the Anglian Breast a Cys allele frequency of 0; exact 95% CI 0-8%). However, In order to establish linkage disequilibrium between the 40 cycles of 95°C for 1 min, 55°C for 1 min, 72°C for 1 min; 1 cycle of [TTTA] n tract and the TCT Ins/Del polymorphism, the relative 72°C for 10 min in an MJ Tetrad PCR machine (GRI, UK). The PCR was sizes of the bands from the two PCR fragments including and then electrophoresed through a sequagel-6 matrix (National Diagnostics) at excluding the TCT (PolyF and PolyR versus I4F and I4R, 120 W until the xylene cyanol dye reached the bottom. The gel was exposed to X-ray film at -70°C overnight. [TTTA] 8 gives a fragment of 175 bp. respectively) were compared. Any haplotype with the TCT The same fragment was amplified for sequence analysis using the same deletion stayed in the same relative position (Figure 1a and b, PCR conditions as above, but excluding [α-32 P]dCTP and using 200 µM lanes E and G), while haplotypes without the deletion decreased dNTPs. The Sequenase PCR product sequencing kit (US Biochemical) was in relative size by 3 bp (e.g. Figure 1a and b, lanes E and F). used according to the manufacturer's instructions.
A second set of primers for [TTTA] n microsatellite analysis in intron 4
There is strong linkage disequilibrium between TCT Ins/Del were designed to exclude the TCT insertion/deletion (Ins/Del) site: I4F, and the [TTTA] n tract (∆ ϭ 0.764, 95% CI 0.735-0.790),
TTGTCTATGAATGTGCCTTTT; I4R, CTGGGTGATAGAGTCAGAGC. These with allelic association between the TCT deletion allele and were used in microsatellite analysis as described above. [TTTA] 8 in this [TTTA] 7 . Similarly, there is also strong linkage disequilibrium instance gives a fragment of 105 bp.
between the intron 6 G→T polymorphism and the [TTTA] n Single-strand conformation polymorphism (SSCP) and sequence analysis of intron 6/exon 7 were performed as for intron 4 but using the primers I6F tract (∆ ϭ 0.964, 95% CI 0.955-0.971), such that three (TCTTAGCTAACTCTGGCACC) and I7R (TTCAGGTCAGTACCTCTGCT) common haplotypes account for 98% of all haplotypes seen and 1.5 mM MgCl 2 in a 50 µl volume and annealing at 60°C, to give a (Table II) . 
Association with breast cancer Statistics
Each polymorphism has been examined for any association Associations between polymorphisms and breast cancer were analysed by with an increased risk of breast cancer. For the [TTTA] n logistic regression using the program S-plus. Cases and controls were polymorphism we compared allele frequencies between cases genotyped in two groups where possible, stratum 1 (up to 288 cases and 288 and controls to look for any association with breast cancer controls) and stratum 2 (up to 384 cases and 384 controls), and all analyses allowed for strata as a covariate. The effects of the TTTA repeats were risk and no significant differences were observed (Table I) . Alleles observed using primers Poly F and R (16). the cases and controls was observed for any genotype in either polymorphism (Tables III and IV) . We particularly looked at the TTTA repeat alleles reported to have an association with increased risk of breast cancer, namely the [TTTA] 12 allele carriers (19) , the [TTTA] n allele 2 (21) and the [TTTA] 10 allele (20) ; none of these associations were apparent in our population. Four studies have now reported on the CYP19 TTTA repeat alleles. We have performed a meta-analysis on the combined results. There is borderline evidence that the [TTTA] 12 carriers (19) and [TTTA] n allele 2 (21) have an increased risk of breast small, only 18 were seen in 2892 controls (0.6%) in the three studies combined, so some of the variation could be due to small sample size.
As the synthesis of oestrogens in post-menopausal women Logistic regression was used to compare the trend in [TTTA] n genotype distribution (mean repeat length of an individuals occurs principally in the adipose tissue, variation in aromatase activity in this subset of women may be of greater importance two alleles) between cases and controls: none is apparent for each extra repeat carried (OR 1.02, 95% CI 0.97-1.07). In to breast cancer risk. Hence, we examined the effects of CYP19 genotype on breast cancer risk in post-menopausal cases addition, genotype distributions between cases and controls for the intron 4 TCT Ins/Del and the intron 6 G→T poly-(defined as women Ͼ55 years old) and controls, but still no association was observed. morphisms were compared. No significant difference between
Discussion
CYP19 gene may exist which have an effect on the expression or activity of Cyp19 in certain tissues. These could, in turn, Given that oestrogens affect breast cancer risk and breast alter levels of oestrogen metabolites and affect breast cancer tissue growth, an attractive hypothesis is that variants in the risk in particular subsets of females. More detailed epidemio-CYP19 gene which alter the ability of the enzyme to convert logical studies are required to test these possibilities. androgens to oestrogens might affect breast cancer risk.
There has been only one polymorphism in the CYP19 gene
